Last Updated: November 8, 2026

EPIDUO FORTE Drug Patent Profile

« Back to Dashboard


Which patents cover Epiduo Forte, and what generic alternatives are available?

Epiduo Forte is a drug marketed by Galderma Labs and is included in one NDA.

The generic ingredient in EPIDUO FORTE is adapalene; benzoyl peroxide. There is one drug master file entry for this compound. Thirteen suppliers are listed for this compound. Additional details are available on the adapalene; benzoyl peroxide profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Epiduo Forte

A generic version of EPIDUO FORTE was approved as adapalene; benzoyl peroxide by PADAGIS ISRAEL on January 23rd, 2018.

  Start Trial

AI Deep Research
Questions you can ask:
  • What is the 5 year forecast for EPIDUO FORTE?
  • What are the global sales for EPIDUO FORTE?
  • What is Average Wholesale Price for EPIDUO FORTE?
Recent Clinical Trials for EPIDUO FORTE

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Bausch Health Americas, Inc.Phase 2
BeiersdorfPhase 2
Mahidol UniversityPhase 2

See all EPIDUO FORTE clinical trials

Paragraph IV (Patent) Challenges for EPIDUO FORTE
Tradename Dosage Ingredient Strength NDA ANDAs Submitted Submissiondate
EPIDUO FORTE Gel adapalene; benzoyl peroxide 0.3%/2.5% 207917 1 2016-05-04

US Patents and Regulatory Information for EPIDUO FORTE

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Galderma Labs EPIDUO FORTE adapalene; benzoyl peroxide GEL;TOPICAL 207917-001 Jul 15, 2015 AB RX Yes Yes ⤷  Start Trial ⤷  Start Trial ⤷  Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for EPIDUO FORTE

International Patents for EPIDUO FORTE

When does loss-of-exclusivity occur for EPIDUO FORTE?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

China

Patent: 1541320
Patent: Combination of adapalene and benzoyl peroxide for treating acne lesions
Estimated Expiration: ⤷  Start Trial

Denmark

Patent: 46318
Estimated Expiration: ⤷  Start Trial

Patent: 50035
Estimated Expiration: ⤷  Start Trial

Japan

Patent: 09542779
Estimated Expiration: ⤷  Start Trial

Patent: 14040481
Patent: COMBINATIONS OF ADAPALENE AND BENZOYL PEROXIDE FOR TREATING ACNE LESIONS
Estimated Expiration: ⤷  Start Trial

Poland

Patent: 46318
Estimated Expiration: ⤷  Start Trial

Patent: 50035
Estimated Expiration: ⤷  Start Trial

Portugal

Patent: 46318
Estimated Expiration: ⤷  Start Trial

Russian Federation

Patent: 09104949
Patent: КОМБИНАЦИЯ АДАПАЛЕНА И ПЕРОКСИДА БЕНЗОИЛА ДЛЯ ЛЕЧЕНИЯ ПОРАЖЕНИЙ АКНЕ
Estimated Expiration: ⤷  Start Trial

Slovenia

Patent: 50035
Estimated Expiration: ⤷  Start Trial

Spain

Patent: 23951
Estimated Expiration: ⤷  Start Trial

Turkey

Patent: 1819658
Estimated Expiration: ⤷  Start Trial

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering EPIDUO FORTE around the world.

Country Patent Number Title Estimated Expiration
Argentina 061989 COMBINACION DE PEROXIDO DE ADAPALENO Y BENZOILO PARA EL TRATAMIENTO DE LESIONES DE ACNE ⤷  Start Trial
Australia 2007274288 Combination of adapalene and benzoyl peroxide for treating acne lesions ⤷  Start Trial
Brazil PI0713182 usos de adapaleno de um de seus sais farmaceuticamente aceitáveis, kit e produto ⤷  Start Trial
Canada 2656456 ADAPALENE ET PEROXYDE DE BENZOYLE COMBINES UTILISES DANS LE TRAITEMENT DE LESIONS DUES A L'ACNE (COMBINATION OF ADAPALENE AND BENZOYL PEROXIDE FOR TREATING ACNE LESIONS) ⤷  Start Trial
China 101541320 Combination of adapalene and benzoyl peroxide for treating acne lesions ⤷  Start Trial
>Country >Patent Number >Title >Estimated Expiration

Supplementary Protection Certificates for EPIDUO FORTE

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
1458369 CA 2008 00029 Denmark ⤷  Start Trial PRODUCT NAME: ADAPALEN, BENZOYLPEROXID
1458369 08C0024 France ⤷  Start Trial PRODUCT NAME: ADAPALENE - PEROXYDE DE BENZOLE; REGISTRATION NO/DATE IN FRANCE: NL 33724 DU 20080123; REGISTRATION NO/DATE AT EEC: 40440 DU 20071218
1458369 SPC/GB10/005 United Kingdom ⤷  Start Trial PRODUCT NAME: ADAPALENE AND BENZOYL PEROXIDE; REGISTERED: DK 40440 20071218; UK PL10590/0057 20091111
1458369 C01458369/01 Switzerland ⤷  Start Trial PRODUCT NAME: ADAPALENUM + BENZOYLIS PEROXIDUM; REGISTRATION NUMBER/DATE: SWISSMEDIC 58460 19.05.2009
1458369 380 Finland ⤷  Start Trial
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.